Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.75
BABY's Cash-to-Debt is ranked lower than
57% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. BABY: 0.75 )
Ranked among companies with meaningful Cash-to-Debt only.
BABY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.32  Med: 50.8 Max: No Debt
Current: 0.75
Equity-to-Asset 0.61
BABY's Equity-to-Asset is ranked higher than
53% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. BABY: 0.61 )
Ranked among companies with meaningful Equity-to-Asset only.
BABY' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.79  Med: 0.82 Max: 0.94
Current: 0.61
-1.79
0.94
Interest Coverage 32.96
BABY's Interest Coverage is ranked higher than
53% of the 222 Companies
in the Global Medical Devices industry.

( Industry Median: 86.37 vs. BABY: 32.96 )
Ranked among companies with meaningful Interest Coverage only.
BABY' s Interest Coverage Range Over the Past 10 Years
Min: 10.45  Med: 100.22 Max: 151.91
Current: 32.96
10.45
151.91
Piotroski F-Score: 6
Altman Z-Score: 4.02
Beneish M-Score: -2.78
WACC vs ROIC
6.81%
10.69%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 10.84
BABY's Operating Margin % is ranked higher than
79% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. BABY: 10.84 )
Ranked among companies with meaningful Operating Margin % only.
BABY' s Operating Margin % Range Over the Past 10 Years
Min: -4.44  Med: 11.48 Max: 15.75
Current: 10.84
-4.44
15.75
Net Margin % 8.21
BABY's Net Margin % is ranked higher than
79% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.55 vs. BABY: 8.21 )
Ranked among companies with meaningful Net Margin % only.
BABY' s Net Margin % Range Over the Past 10 Years
Min: -4.8  Med: 7.55 Max: 11.15
Current: 8.21
-4.8
11.15
ROE % 8.45
BABY's ROE % is ranked higher than
72% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. BABY: 8.45 )
Ranked among companies with meaningful ROE % only.
BABY' s ROE % Range Over the Past 10 Years
Min: -4.28  Med: 8.52 Max: 10.54
Current: 8.45
-4.28
10.54
ROA % 6.13
BABY's ROA % is ranked higher than
80% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 0.06 vs. BABY: 6.13 )
Ranked among companies with meaningful ROA % only.
BABY' s ROA % Range Over the Past 10 Years
Min: -3.46  Med: 5.94 Max: 8.3
Current: 6.13
-3.46
8.3
ROC (Joel Greenblatt) % 43.30
BABY's ROC (Joel Greenblatt) % is ranked higher than
90% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 4.26 vs. BABY: 43.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BABY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -12.53  Med: 41.37 Max: 56.94
Current: 43.3
-12.53
56.94
3-Year Revenue Growth Rate 1.10
BABY's 3-Year Revenue Growth Rate is ranked lower than
64% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. BABY: 1.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BABY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -61.9  Med: 10.65 Max: 38.3
Current: 1.1
-61.9
38.3
3-Year EBITDA Growth Rate 13.20
BABY's 3-Year EBITDA Growth Rate is ranked higher than
56% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. BABY: 13.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BABY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -88.5  Med: 22.8 Max: 863.2
Current: 13.2
-88.5
863.2
3-Year EPS without NRI Growth Rate 19.80
BABY's 3-Year EPS without NRI Growth Rate is ranked higher than
72% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. BABY: 19.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BABY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -52.8  Med: -1.6 Max: 106.2
Current: 19.8
-52.8
106.2
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BABY's 30-Y Financials

Financials (Next Earnings Date: 2017-07-20 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

BABY Guru Trades in Q2 2016

Steven Cohen 622,600 sh (New)
Robert Olstein 57,025 sh (New)
Joel Greenblatt 280,046 sh (+231.17%)
Ken Fisher 589,798 sh (+0.06%)
Diamond Hill Capital 591,256 sh (unchged)
Jim Simons Sold Out
» More
Q3 2016

BABY Guru Trades in Q3 2016

Columbia Wanger 265,000 sh (New)
Jim Simons 13,200 sh (New)
Ken Fisher 611,816 sh (+3.73%)
Steven Cohen Sold Out
Diamond Hill Capital 589,744 sh (-0.26%)
Robert Olstein 55,850 sh (-2.06%)
Joel Greenblatt 142,710 sh (-49.04%)
» More
Q4 2016

BABY Guru Trades in Q4 2016

Paul Tudor Jones 16,520 sh (New)
Steven Cohen 74,900 sh (New)
Jim Simons 45,800 sh (+246.97%)
Columbia Wanger 590,825 sh (+122.95%)
Robert Olstein 77,795 sh (+39.29%)
Joel Greenblatt 147,129 sh (+3.10%)
Diamond Hill Capital 589,551 sh (-0.03%)
Ken Fisher 610,049 sh (-0.29%)
» More
Q1 2017

BABY Guru Trades in Q1 2017

Mariko Gordon 1,300,949 sh (New)
Columbia Wanger 2,030,207 sh (+243.62%)
Jim Simons 149,294 sh (+225.97%)
Robert Olstein 86,845 sh (+11.63%)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Ken Fisher 597,674 sh (-2.03%)
Diamond Hill Capital 575,594 sh (-2.37%)
Joel Greenblatt 112,248 sh (-23.71%)
» More
» Details

Insider Trades

Latest Guru Trades with BABY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:OTCPK:MZRTF, OTCPK:MCRPF, OTCPK:NMRD, NAS:CSII, NAS:SPNC, NYSE:ITGR, NAS:KTWO, NAS:CNMD, NAS:OFIX, OTCPK:CSRMY, NAS:XENT, NAS:MDXG, NAS:CYNO, NAS:GNMK, NYSE:CRY, OTCPK:IOBCF, NAS:INGN, NAS:AXGN, NYSE:IVC, NAS:EXAC » details
Traded in other countries:NM4.Germany,
Headquarter Location:USA
Natus Medical Inc provides newborn care & neurology healthcare products & services used for screening, diagnosis, detection, treatment, monitoring & tracking of medical ailments in newborn care, epilepsy, sleep disorders, and balance & mobility disorders.

Natus Medical Inc was incorporated in California in May 1987 and reincorporated in Delaware in August 2000. The company is a provider of newborn care and neurology healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. The company offers two product families: Neurology and Newborn Care. Neurology includes products for diagnostic electroencephalography (EEG), electromyography (EMG), diagnostic sleep analysis or polysomnography (PSG), intra-operative monitoring (IOM), and transcranial doppler ultrasound technology. Newborn Care includes products for newborn care including hearing screening, brain injury, thermoregulation, jaundice management, and various disposable products, as well as products for diagnostic hearing assessment for children through adult populations, and products to diagnose and assist in treating balance and mobility disorders. The company is subject to inspection and market surveillance by the FDA to determine compliance with regulatory requirements.

Top Ranked Articles about Natus Medical Inc

Natus Medical to Host Analyst Day on June 22nd
Natus Medical to Hold 2017 First Quarter Financial Results Conference Call on April 26th
NATUS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Natus Medical Incorporated – (BABY)

NEW ORLEANS, March 24, 2017 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., reminds investors that they have until March 31, 2017 to file lead plaintiff applications in a securities class action lawsuit against Natus Medical Incorporated (NASDAQ:BABY), if they purchased the Company’s shares between October 16, 2015 and April 3, 2016, inclusive (the “Class Period”).  The action is pending in United States District Court for the Northern District of California. 
What You May Do If you purchased shares of Natus and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by March 31, 2017. About the Lawsuit Natus and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.  The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Venezuelan government had not made tens of millions of dollars in prepayments to Natus under their three-year supply contract ("Supply Contract"); (ii) Natus had no means to effectively enforce the Supply Contract, as Venezuela was the exclusive forum for dispute resolution; (iii) Natus's receipt of revenues under the Supply Contract was contingent on the Venezuelan elections; and (iv) accordingly, Natus was not on track to achieve the increased guidance it provided and such guidance lacked a reasonable basis.  About Kahn Swick & Foti, LLC KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana. To learn more about KSF, you may visit www.ksfcounsel.com

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
206 Covington St.
Madisonville, LA 70447

Read more...
BABY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Natus Medical Incorporated and a Lead Plaintiff Deadline of March 31, 2017

NEW YORK, March 24, 2017 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased Natus Medical Incorporated (NASDAQ:BABY) securities between October 16, 2015 and April 3, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/natus-medical-incorporated. There is no cost or obligation to you. According to the complaint, throughout the Class Period Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts, including that: (1) the Venezuelan government failed to make tens of millions of dollars in prepayments to Natus, which were required to have been paid beginning in October 2015; (2) Natus had no means to effectively enforce its rights under its supply contract, as Venezuela was the exclusive forum for dispute resolution; (3) Natus’ receipt of revenues pursuant to the supply contract was contingent on the outcome of Venezuelan elections; and (4) as a result, Natus was not on track to achieve the increased guidance provided by Defendants, which lacked a reasonable basis. If you suffered a loss in Natus you have until March 31, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/natus-medical-incorporated. Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights.  Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

Read more...
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Natus Medical Incorporated (BABY) & Lead Plaintiff Deadline: March 31, 2017

NEW YORK, March 23, 2017 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Natus Medical Incorporated (“Natus” or the “Company”) (NASDAQ:BABY) and certain of its officers, and is on behalf of shareholders who purchased or otherwise acquired Natus Medical Incorporated securities between October 16, 2015 and April 3, 2016, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/baby. The class action lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”). The Complaint that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose material adverse facts about Natus’ business, operations, and prospects, including that: (1) the Venezuelan government failed to make tens of millions of dollars in prepayments to Natus, which were required to have been paid beginning in October 2015; (2) Natus had no means to effectively enforce its rights under its supply contract, as Venezuela was the exclusive forum for dispute resolution; (3) Natus’ receipt of revenues pursuant to the supply contract was contingent on the outcome of Venezuelan elections; and (4) consequently, Natus was not on track to achieve the increased guidance provided by Defendants, which lacked a reasonable basis.  Once this information was made known to the investing public, the lawsuit claims that investors suffered damages. A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/baby  or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Natus you have until March 31, 2017 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.  

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]

Read more...
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Natus Medical Incorporated and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, March 18, 2017 (GLOBE NEWSWIRE) -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Natus Medical Incorporated (“Natus” or the “Company”) (NASDAQ:BABY). Investors who purchased or otherwise acquired Natus shares between October 16, 2015 and April 3, 2016 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 31, 2016 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected]. No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member. According to the Complaint, during the Class Period, Natus released materially false and/or misleading statements, as well as failed to disclose material adverse facts about its business, operations, and prospects, including that: the government of Venezuela was unable to spend tens of millions of dollars in prepayments to Natus, needed in October 2015; that Natus did not have the capacity to effectively enforce its rights under its supply contract; Natus’ revenues related to the supply contract were dependent on the results of Venezuelan elections; and as therefore, Natus could not actually achieve the increased guidance offered by Defendants, which lacked a reasonable basis. When this information was revealed to the public, the value of Natus Medical Incorporated stock declined, causing investors harm. Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
[email protected]
http://lundinlawpc.com/

Read more...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Natus Medical Incorporated of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 31, 2017 – BABY

NEW YORK, March 17, 2017 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Natus Medical Incorporated (“Natus”) (NASDAQ:BABY) between October 16, 2015 and April 3, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Northern District of California. To get more information go to: http://www.zlk.com/pslra/natus-medical-incorporated or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you. The complaint alleges that throughout the Class Period Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts, including that: (1) the Venezuelan government failed to make tens of millions of dollars in prepayments to Natus, which were required to have been paid beginning in October 2015; (2) Natus had no means to effectively enforce its rights under its supply contract, as Venezuela was the exclusive forum for dispute resolution; (3) Natus’ receipt of revenues pursuant to the supply contract was contingent on the outcome of Venezuelan elections; and (4) as a result, Natus was not on track to achieve the increased guidance provided by Defendants, which lacked a reasonable basis.  If you suffered a loss in Natus you have until March 31, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

Read more...
Natus Medical Investor Deadline Reminder: Hagens Berman Reminds Investors in Natus Medical of the March 31, 2017 Lead Plaintiff Deadline

SAN FRANCISCO, March 17, 2017 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP reminds investors in Natus Medical, Inc. (NASDAQ:BABY) of the March 31, 2017 Lead Plaintiff deadline in the pending securities class action.
If you purchased or otherwise acquired securities of BABY between October 16, 2015 and April 3, 2016 and suffered losses contact Hagens Berman Sobol Shapiro LLP.  For more information visit: https://www.hbsslaw.com/cases/BABY or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected]. On October 15, 2015, Natus announced it would supply the Venezuelan government with medical equipment, supplies and services over a three year period.  The Company stated “[p]repayments totaling approximately $69 million are expected by the first quarter of 2016[]” and “[i]f fully performed, the total sales under the agreement would aggregate $232.5 million.” However, by January 11, 2016, Natus had yet to receive a payment from the Venezuelan government and the Company reduced its fourth quarter 2015 revenue guidance from $102 - $105 million to approximately $100 million.  That day, Natus’ stock closed at $38.25 per share, over 11% lower than the previous closing price of $43.20 per share. On February 29, 2016, Natus filed its Form 10-K which attached a copy of the Venezuelan contract.  The contract specified that the $69 million prepayments were due by the end of the fourth quarter of 2015. By April 4, 2016, Natus announced it had again failed to secure any money from the Venezuelan government and the Company reduced its first quarter 2016 revenue guidance from $91.5 - $92.5 million to $87.5 million.  Natus’ stock closed at $31.84 per share that day – down over 19%.  SEC filings show the Company’s CEO (James Hawkins) and CFO (Jonathan Kennedy) together sold over $10.7 million of their shares between October and December 2015. “Among other things, we’re concerned about insider selling, especially considering Defendants’ announcements and the Company’s twice-reduced guidance,” said Hagens Berman partner Reed Kathrein. Whistleblowers: Persons with non-public information regarding BABY should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.  Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.  For more information, call Reed Kathrein at 510-725-3000 or email [email protected]. About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities.  The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com.  For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 510-725-3000


Read more...
NATUS LOSS ALERT: Rosen Law Firm Reminds Natus Medical Incorporated Investors of Important Deadline in Class Action – BABY

NEW YORK, March 10, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Natus Medical Incorporated securities (NASDAQ:BABY) from October 16, 2015 through April 3, 2016, inclusive (the “Class Period”) of the important March 31, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Natus investors under the federal securities laws. To join the Natus class action, go to http://rosenlegal.com/cases-1045.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. According to the lawsuit, throughout the Class Period Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about Natus’ business, operations, and prospects, including that: (1) the Venezuelan government failed to make tens of millions of dollars in prepayments to Natus, which were required to have been paid beginning in October 2015; (2) Natus had no means to effectively enforce its rights under its supply contract, as Venezuela was the exclusive forum for dispute resolution; (3) Natus’ receipt of revenues pursuant to the supply contract was contingent on the outcome of Venezuelan elections; and (4) as a result, Natus was not on track to achieve the increased guidance provided by Defendants, which lacked a reasonable basis.  When the true details entered the market, the lawsuit claims that investors suffered damages. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 31, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1045.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected]. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm. Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


Read more...
Weekly CEO Buys Highlight Insiders invest in Natus, OPKO, Mobile Mini, S&T Bancorp, Investors Real Estate
According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...

Ratios

vs
industry
vs
history
PE Ratio 32.17
BABY's PE Ratio is ranked lower than
53% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 27.53 vs. BABY: 32.17 )
Ranked among companies with meaningful PE Ratio only.
BABY' s PE Ratio Range Over the Past 10 Years
Min: 11.26  Med: 34.99 Max: 436.67
Current: 32.17
11.26
436.67
Forward PE Ratio 20.28
BABY's Forward PE Ratio is ranked lower than
54% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 21.79 vs. BABY: 20.28 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 32.17
BABY's PE Ratio without NRI is ranked lower than
54% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 27.51 vs. BABY: 32.17 )
Ranked among companies with meaningful PE Ratio without NRI only.
BABY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.26  Med: 34.99 Max: 436.67
Current: 32.17
11.26
436.67
Price-to-Owner-Earnings 32.23
BABY's Price-to-Owner-Earnings is ranked higher than
67% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 32.96 vs. BABY: 32.23 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BABY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 18.79  Med: 38.82 Max: 8415
Current: 32.23
18.79
8415
PB Ratio 2.64
BABY's PB Ratio is ranked higher than
51% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. BABY: 2.64 )
Ranked among companies with meaningful PB Ratio only.
BABY' s PB Ratio Range Over the Past 10 Years
Min: 0.79  Med: 2.46 Max: 4.26
Current: 2.64
0.79
4.26
PS Ratio 2.66
BABY's PS Ratio is ranked lower than
53% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. BABY: 2.66 )
Ranked among companies with meaningful PS Ratio only.
BABY' s PS Ratio Range Over the Past 10 Years
Min: 0.95  Med: 2.56 Max: 4.44
Current: 2.66
0.95
4.44
Price-to-Free-Cash-Flow 21.17
BABY's Price-to-Free-Cash-Flow is ranked higher than
66% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 27.61 vs. BABY: 21.17 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BABY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.63  Med: 30.85 Max: 521.25
Current: 21.17
12.63
521.25
Price-to-Operating-Cash-Flow 20.20
BABY's Price-to-Operating-Cash-Flow is ranked higher than
54% of the 140 Companies
in the Global Medical Devices industry.

( Industry Median: 20.26 vs. BABY: 20.20 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BABY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.19  Med: 25.29 Max: 108.31
Current: 20.2
10.19
108.31
EV-to-EBIT 25.42
BABY's EV-to-EBIT is ranked higher than
60% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 24.54 vs. BABY: 25.42 )
Ranked among companies with meaningful EV-to-EBIT only.
BABY' s EV-to-EBIT Range Over the Past 10 Years
Min: -29.6  Med: 23.2 Max: 112
Current: 25.42
-29.6
112
EV-to-EBITDA 17.76
BABY's EV-to-EBITDA is ranked higher than
58% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 19.31 vs. BABY: 17.76 )
Ranked among companies with meaningful EV-to-EBITDA only.
BABY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -82.2  Med: 17 Max: 5653.1
Current: 17.76
-82.2
5653.1
PEG Ratio 0.16
BABY's PEG Ratio is ranked higher than
98% of the 83 Companies
in the Global Medical Devices industry.

( Industry Median: 2.52 vs. BABY: 0.16 )
Ranked among companies with meaningful PEG Ratio only.
BABY' s PEG Ratio Range Over the Past 10 Years
Min: 0.16  Med: 1.17 Max: 2.38
Current: 0.16
0.16
2.38
Shiller PE Ratio 54.92
BABY's Shiller PE Ratio is ranked lower than
64% of the 50 Companies
in the Global Medical Devices industry.

( Industry Median: 49.41 vs. BABY: 54.92 )
Ranked among companies with meaningful Shiller PE Ratio only.
BABY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 43.71  Med: 80.01 Max: 115
Current: 54.92
43.71
115
Current Ratio 3.70
BABY's Current Ratio is ranked higher than
83% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. BABY: 3.70 )
Ranked among companies with meaningful Current Ratio only.
BABY' s Current Ratio Range Over the Past 10 Years
Min: 1.3  Med: 3.26 Max: 16.01
Current: 3.7
1.3
16.01
Quick Ratio 2.91
BABY's Quick Ratio is ranked higher than
83% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. BABY: 2.91 )
Ranked among companies with meaningful Quick Ratio only.
BABY' s Quick Ratio Range Over the Past 10 Years
Min: 0.91  Med: 2.57 Max: 15.09
Current: 2.91
0.91
15.09
Days Inventory 109.73
BABY's Days Inventory is ranked higher than
55% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 130.04 vs. BABY: 109.73 )
Ranked among companies with meaningful Days Inventory only.
BABY' s Days Inventory Range Over the Past 10 Years
Min: 104.01  Med: 123.48 Max: 132.84
Current: 109.73
104.01
132.84
Days Sales Outstanding 99.59
BABY's Days Sales Outstanding is ranked lower than
64% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.94 vs. BABY: 99.59 )
Ranked among companies with meaningful Days Sales Outstanding only.
BABY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 81.74  Med: 86.98 Max: 112.34
Current: 99.59
81.74
112.34
Days Payable 55.39
BABY's Days Payable is ranked lower than
61% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. BABY: 55.39 )
Ranked among companies with meaningful Days Payable only.
BABY' s Days Payable Range Over the Past 10 Years
Min: 44.18  Med: 67.82 Max: 92.09
Current: 55.39
44.18
92.09

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.60
BABY's 3-Year Average Share Buyback Ratio is ranked higher than
66% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. BABY: -1.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BABY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -185.4  Med: -3.4 Max: -1.6
Current: -1.6
-185.4
-1.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 23.15
BABY's Price-to-Net-Current-Asset-Value is ranked lower than
53% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: 6.88 vs. BABY: 23.15 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BABY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.09  Med: 6.58 Max: 2050
Current: 23.15
1.09
2050
Price-to-Tangible-Book 10.70
BABY's Price-to-Tangible-Book is ranked lower than
63% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.11 vs. BABY: 10.70 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BABY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.02  Med: 5.04 Max: 64.5
Current: 10.7
1.02
64.5
Price-to-Intrinsic-Value-Projected-FCF 1.64
BABY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
60% of the 129 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. BABY: 1.64 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BABY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.79  Med: 1.7 Max: 73.21
Current: 1.64
0.79
73.21
Price-to-Median-PS-Value 1.04
BABY's Price-to-Median-PS-Value is ranked lower than
71% of the 242 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. BABY: 1.04 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BABY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.12  Med: 1 Max: 2.87
Current: 1.04
0.12
2.87
Price-to-Peter-Lynch-Fair-Value 7.60
BABY's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 57 Companies
in the Global Medical Devices industry.

( Industry Median: 1.61 vs. BABY: 7.60 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BABY' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.58  Med: 1.5 Max: 7.64
Current: 7.6
0.58
7.64
Price-to-Graham-Number 3.93
BABY's Price-to-Graham-Number is ranked lower than
59% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. BABY: 3.93 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BABY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.18  Med: 3.07 Max: 33.61
Current: 3.93
1.18
33.61
Earnings Yield (Greenblatt) % 3.94
BABY's Earnings Yield (Greenblatt) % is ranked higher than
75% of the 432 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. BABY: 3.94 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BABY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.9  Med: 4.2 Max: 19.5
Current: 3.94
0.9
19.5
Forward Rate of Return (Yacktman) % 12.99
BABY's Forward Rate of Return (Yacktman) % is ranked higher than
61% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 8.85 vs. BABY: 12.99 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BABY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -1.5  Med: 3.1 Max: 75
Current: 12.99
-1.5
75

More Statistics

Revenue (TTM) (Mil) $419.2
EPS (TTM) $ 1.04
Beta0.83
Short Percentage of Float8.25%
52-Week Range $31.84 - 44.39
Shares Outstanding (Mil)33.09

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 504 517
EPS ($) 1.67 1.96
EPS without NRI ($) 1.67 1.96
EPS Growth Rate
(Future 3Y To 5Y Estimate)
22.00%
Dividends per Share ($)
» More Articles for BABY

Headlines

Articles On GuruFocus.com
Natus Medical to Host Analyst Day on June 22nd May 11 2017 
Natus Medical to Hold 2017 First Quarter Financial Results Conference Call on April 26th Apr 12 2017 
NATUS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTO Mar 25 2017 
BABY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involvin Mar 24 2017 
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Natus M Mar 23 2017 
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Natus Medi Mar 18 2017 
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Natus Medical Incorporated of a Cla Mar 17 2017 
Natus Medical Investor Deadline Reminder: Hagens Berman Reminds Investors in Natus Medical of the Ma Mar 17 2017 
NATUS LOSS ALERT: Rosen Law Firm Reminds Natus Medical Incorporated Investors of Important Deadline Mar 10 2017 
Weekly CEO Buys Highlight Dec 27 2016 

More From Other Websites
Natus Medical to Host Analyst Day on June 22nd May 11 2017
Natus Medical Inc. Fell 11% in April. Here's Why. May 08 2017
Natus Medical, Inc. – Value Analysis (NASDAQ:BABY) : April 28, 2017 Apr 28 2017
Edited Transcript of BABY earnings conference call or presentation 26-Apr-17 3:00pm GMT Apr 27 2017
Natus Medical Inc: This BABY Has Some Growing Pains Apr 27 2017
Natus Medical, Inc. breached its 50 day moving average in a Bearish Manner : BABY-US : April 27,... Apr 27 2017
Why Natus Medical Inc. Sank Today Apr 26 2017
Natus Medical misses 1Q profit forecasts Apr 26 2017
Natus Medical Announces First Quarter 2017 Financial Results Apr 26 2017
Lawsuit for Investors in NASDAQ: BABY Shares Against Natus Medical Inc. Announced by Shareholders... Apr 25 2017
Natus Medical to Hold 2017 First Quarter Financial Results Conference Call on April 26th Apr 12 2017
DEADLINE TOMORROW: Lundin Law PC Announces Securities Class Action Lawsuit against Natus Medical... Mar 30 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Natus Medical Incorporated of a Class... Mar 30 2017
MARCH 31 DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Natus Medical... Mar 29 2017
NATUS 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and... Mar 28 2017
SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Natus Medical... Mar 28 2017
3 Top Medical Device Stocks to Buy in 2017 Mar 28 2017
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against... Mar 27 2017
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Investors in Natus Medical Incorporated of Upcoming... Mar 25 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat